QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-neutral-on-alnylam-pharmaceuticals-raises-price-target-to-248

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and raises the price target fro...

 top-performing-industry-etfs-in-june-software-leads-returns-chipmakers-attract-most-inflows

June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while ut...

 cantor-fitzgerald-reiterates-neutral-on-alnylam-pharmaceuticals-maintains-150-price-target

Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and maintains $150 p...

 rivian-automotive-and-carvana-were-among-the-10-biggest-large-cap-gainers-last-week-june-23-june-29-are-these-in-your-portfolio

The top 10 large-cap stocks in the last week were RIVN, CUK, FDX, IOT, SUZ, CVNA, FTAI, RDDT, MDB, and ALNY. Many analysts have...

 ubs-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-288

UBS analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $253 to...

 rbc-capital-maintains-outperform-on-alnylam-pharmaceuticals-raises-price-target-to-265

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target ...

 stifel-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-295

Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $215...

 citigroup-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-291

Citigroup analyst David Lebovitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from...

 b-of-a-securities-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-295

B of A Securities maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $248 to $295.

 leerink-partners-maintains-market-perform-on-alnylam-pharmaceuticals-raises-price-target-to-159

Leerink Partners maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and raises the price target from $138 ...

 td-cowen-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-282

TD Cowen analyst Ritu Baral maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $260...

 evercore-isi-group-maintains-outperform-on-alnylam-pharmaceuticals-raises-price-target-to-260

Evercore ISI Group analyst Liisa Bayko maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the pric...

 barclays-maintains-overweight-on-alnylam-pharmaceuticals-raises-price-target-to-291

Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target fro...

 rbc-capital-maintains-outperform-on-alnylam-pharmaceuticals-raises-price-target-to-250

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target ...

 wells-fargo-maintains-equal-weight-on-alnylam-pharmaceuticals-raises-price-target-to-207

Wells Fargo analyst Tiago Fauth maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price tar...

 morgan-stanley-maintains-equal-weight-on-alnylam-pharmaceuticals-raises-price-target-to-250

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price ...